Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort.
Jorge Calderón-ParraPablo Guisado VascoRocío Montejano-SánchezVicente EstradaGuillermo Cuevas TascónJosé AguarelesJosé ArribasMarta Erro-IribarrenMarina Calvo-SalvadorAna Fernández CruzAntonio Ramos MartínezElena Muñez-RubioPublished in: Journal of clinical medicine (2023)
Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early onset
- prognostic factors
- electronic health record
- big data
- respiratory failure
- cross sectional
- intensive care unit
- patient reported outcomes
- respiratory syndrome coronavirus
- patient reported
- artificial intelligence